In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
Join experts Roland Buhl, Joaquim Mullol, and Giselle Mosnaim as they discuss the role of type 2 inflammation across the unified airway, with a focus on the amplified burden and the difficulty controlling inflammation when asthma and CRSwNP coexist.

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.

This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.

Giselle Mosnaim is a board-certified allergist and immunologist at Endeavor Health and Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine. An internationally recognized expert in asthma and allergic diseases, her clinical and research interests focus on severe and uncontrolled asthma, digital health, and improving patient outcomes through innovative, evidence-based care.

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

Tune in as Dr. Jason Hawkes describes how to assess disease activity in chronic spontaneous urticaria.